RhumbLine Advisers’s Connect Biopharma Holdings CNTB Stock Holding History

RhumbLine Advisers’s Portfolio CNTB Stock Details CNTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.1K	Buy	10,979 +10,199	+1,308%	+$24.7K	﹤0.01%	3781
2026 Q1	$2.04K	Hold	780	–	–	﹤0.01%	3938
2025 Q4	$2.2K	Hold	780	–	–	﹤0.01%	3987
2025 Q3	$1.15K	Sell	780 -1,590	-67%	-$2.81K	﹤0.01%	4021
2025 Q2	$2.37K	Hold	2,370	–	–	﹤0.01%	3984
2025 Q1	$1.3K	Sell	2,370 -7,130	-75%	-$6.61K	﹤0.01%	4012
2024 Q4	$13.1K	Hold	9,500	–	–	﹤0.01%	3851
2024 Q3	$13.5K	Hold	9,500	–	–	﹤0.01%	3855
2024 Q2	$14.4K	Sell	9,500 -7,020	-42%	-$11.5K	﹤0.01%	3919
2024 Q1	$28.7K	Hold	16,520	–	–	﹤0.01%	3717
2023 Q4	$19.5K	Hold	16,520	–	–	﹤0.01%	3772
2023 Q3	$12.8K	Buy	16,520 +6,585	+66%	+$6K	﹤0.01%	3838
2023 Q2	$11K	Buy	+9,935	New	+$11.1K	﹤0.01%	3922

Other funds holding CNTB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return

DMKJ

David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

RhumbLine Advisers's CNTB Position: Q2 2026 in Review

RhumbLine Advisers increased its Connect Biopharma Holdings (CNTB) stake by 1,308% in Q2 2026, buying an estimated $24.7K and bringing the position to 10,979 shares worth $26.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3781.

RhumbLine Advisers first reported a position in CNTB in Q2 2023 and has held it in 13 quarters since. The position peaked at $28.7K in Q1 2024. 34 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

RhumbLine Advisers held 10,979 shares of Connect Biopharma Holdings worth $26.1K as of Q2 2026.
RhumbLine Advisers bought 10,199 Connect Biopharma Holdings shares in Q2 2026, an estimated $24.7K.
Connect Biopharma Holdings made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3781 holding.
RhumbLine Advisers first reported a position in Connect Biopharma Holdings in Q2 2023 and has held it in 13 quarters since.
RhumbLine Advisers's Connect Biopharma Holdings position peaked at $28.7K in Q1 2024.
34 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.